Patents Assigned to Daewoong Pharmaceutical Co., Ltd.
  • Patent number: 10981917
    Abstract: The present invention relates to a heterocyclic compound represented by Chemical Formula 1 that can be used for the prevention or treatment of diseases caused by abnormality in a PRS (prolyl-tRNA synthetase) activity, or a pharmaceutically acceptable salt thereof, a method for preparing the same, and a pharmaceutical composition comprising the same.
    Type: Grant
    Filed: February 7, 2018
    Date of Patent: April 20, 2021
    Assignee: Daewoong Pharmaceutical Co., Ltd.
    Inventors: Bong-Yong Lee, Min-Jae Cho, Hyung-Geun Lee, Myung-gi Jung, Yunju Oh
  • Patent number: 10980829
    Abstract: The present invention relates to a composition for dermal injection which includes two or more types of cross-linked hyaluronic acid particles having different particle diameters and non-cross-linked hyaluronic acid. The composition for dermal injection according to the present invention satisfies viscosity, extrusion force, and viscoelasticity conditions for dermal injection, and an extrusion force deviation is low so that the user does not feel fatigue when the composition is injected into the dermal thereof. Also, the composition is excellent in viscoelasticity and tissue restoring ability, is maintained for a long period of time, allows rapid recovery because an initial swelling degree is low, and also is excellent in safety and stability in the body.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: April 20, 2021
    Assignees: CG Bio Co., Ltd., DNCompany, Daewoong Pharmaceutical Co., Ltd.
    Inventors: Ji Sun Lee, Su Hyun Jung, Hak Su Jang, Jung Eun Choo, Hye Young Jung
  • Patent number: 10961247
    Abstract: The present invention relates to a pyrazolopyrimidine derivative, or a pharmaceutically acceptable salt thereof. The compound according to the present invention can be usefully used for the prevention or treatment of diseases which are associated with kinase inhibitory actions.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: March 30, 2021
    Assignee: Daewoong Pharmaceutical Co., Ltd.
    Inventors: In Woo Kim, Mi Ryeong Han, Jakyung Yoo, Yun Ju Oh, Ji Duck Kim, Nam Youn Kim, Sun Ah Jun, Jun Hee Lee, Joon Seok Park
  • Patent number: 10913715
    Abstract: The present invention provides a novel crystalline form I of hydrochloride, a crystalline form II of hydrochloride, a crystalline form of succinate, a crystalline form of tartrate, a crystalline form I of fumarate and a crystalline form II of fumarate of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine. The above-described novel crystalline forms have high solubility in water and excellent stability under moisture-proof conditions and high-humidity exposure conditions, and thus can be pharmaceutically used.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: February 9, 2021
    Assignee: Daewoong Pharmaceutical Co., Ltd.
    Inventors: Aeri Kim, Kwan Hyung Cho
  • Patent number: 10897923
    Abstract: The present invention relates to a method using a SLIT-ROBO system to treat sarcopenia and, more specifically, to a method comprising administration of a gene selected from among slit1, slit2, slit3, robo1, robo2, and fragments thereof, or a protein expressed from the gene as an effective method for treating a muscle disease or for improving muscular function.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: January 26, 2021
    Assignee: DAEWOONG PHARMACEUTICAL CO., LTD.
    Inventor: Jung Min Koh
  • Patent number: 10889574
    Abstract: The present invention relates to an improved method for producing a diphenylmethane derivative which is effective as a sodium-dependent glucose cotransporter (SGLT) inhibitor, the method being carried out by means of a convergent synthesis method in which each major group is separately synthesized and then coupled. As such, in comparison to a linear synthesis method disclosed in existing documents, the synthesis pathway is compact and yield can be increased, and risk factors inherent in the linear synthesis pathway can be reduced. Furthermore, the crystal form of the compound produced according to the method has superb physicochemical characteristics, and thus can be effectively utilized in fields such as pharmaceutical manufacturing.
    Type: Grant
    Filed: August 30, 2019
    Date of Patent: January 12, 2021
    Assignees: DAEWOONG PHARMACEUTICAL CO., LTD., GREEN CROSS CORPORATION
    Inventors: Hee-kyoon Yoon, Se-Hwan Park, Ji-sung Yoon, Soongyu Choi, Hee Jeong Seo, Eun-Jung Park, Younggyu Kong, Kwang-Seop Song, Min Ju Kim, So Ok Park
  • Patent number: 10889545
    Abstract: The present invention provides a novel crystalline form I of hydrochloride, a crystalline form II of hydrochloride, a crystalline form of succinate, a crystalline form of tartrate, a crystalline form I of fumarate and a crystalline form II of fumarate of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine. The above-described novel crystalline forms have high solubility in water and excellent stability under moisture-proof conditions and high-humidity exposure conditions, and thus can be pharmaceutically used.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: January 12, 2021
    Assignee: Daewoong Pharmaceutical Co., Ltd.
    Inventors: Aeri Kim, Kwan Hyung Cho
  • Patent number: 10710961
    Abstract: The present invention relates to a method for preparing intermediates of 4-methoxypyrrole derivatives. The preparation method according to the present invention has advantages that a high-temperature reaction is not required as a whole, inexpensive and non-explosive reagents are used instead of (trimethylsilyl)diazomethane, and further an intermediate of 4-methoxy pyrrole derivatives can be prepared as a whole at a high yield.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: July 14, 2020
    Assignee: Daewoong Pharmaceutical Co., Ltd.
    Inventors: Jeong-Taek Shin, Jeong-Hyun Son, Deok Ki Eom, Chun Ho Lee
  • Patent number: 10683268
    Abstract: The present invention provides a novel crystalline form I of hydrochloride, a crystalline form II of hydrochloride, a crystalline form of succinate, a crystalline form of tartrate, a crystalline form I of fumarate and a crystalline form II of fumarate of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine. The above-described novel crystalline forms have high solubility in water and excellent stability under moisture-proof conditions and high-humidity exposure conditions, and thus can be pharmaceutically used.
    Type: Grant
    Filed: May 14, 2019
    Date of Patent: June 16, 2020
    Assignee: Daewoong Pharmaceutical Co., Ltd.
    Inventors: Aeri Kim, Kwan Hyung Cho
  • Patent number: 10640496
    Abstract: The present invention relates to an improved method for producing a diphenylmethane derivative which is effective as a sodium-dependent glucose cotransporter (SGLT) inhibitor, the method being carried out by means of a convergent synthesis method in which each major group is separately synthesized and then coupled. As such, in comparison to a linear synthesis method disclosed in existing documents, the synthesis pathway is compact and yield can be increased, and risk factors inherent in the linear synthesis pathway can be reduced. Furthermore, the crystal form of the compound produced according to the method has superb physicochemical characteristics, and thus can be effectively utilized in fields such as pharmaceutical manufacturing.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: May 5, 2020
    Assignees: DAEWOONG PHARMACEUTICAL CO., LTD., GREEN CROSS CORPORATION
    Inventors: Hee-kyoon Yoon, Se-Hwan Park, Ji-sung Yoon, Soongyu Choi, Hee Jeong Seo, Eun-Jung Park, Younggyu Kong, Kwang-Seop Song, Min Ju Kim, So Ok Park
  • Publication number: 20200113826
    Abstract: The present invention provides a suspension comprising aluminum hydroxide and magnesium hydroxide and a method of preparing the same. The aqueous suspension composition according to the present invention ensures an excellent sedimentation rate by using a mixed suspending agent with a specific composition, so that insoluble aluminum hydroxide and magnesium hydroxide do not easily settle, do not form a cake, and are easily redispersed. Since the aqueous suspension composition having an excellent sedimentation rate has not only physical stability, but also forms a homogeneous dispersion system, the reproducibility or effectiveness of bioavailability may be ensured. In addition, the aqueous suspension composition according to the present invention provides an excellent texture, and thus patient compliance increases.
    Type: Application
    Filed: April 12, 2018
    Publication date: April 16, 2020
    Applicants: Daewoong Pharmaceutical Co., Ltd., Liaoning Daewoong Pharmaceutical Co,. Ltd.
    Inventors: Ye CHANG, Qing Ri LI, Sang Ho SEOL, Tie LI, Chao TONG
  • Patent number: 10590078
    Abstract: The present invention relates to a compound having a blocking effect against sodium ion channels, particularly Nav1.7, a preparation method thereof and use thereof. The compound represented by the Formula 1 or a pharmaceutically acceptable salt, hydrate, solvate or isomer thereof can be effectively used in the prevention or treatment of pains, for example, acute pain, chronic pain, pain from nervous disease, postoperative pain, migraine, arthralgia, neuropathy, nerve injury, diabetic neuropathy, neuropathic disease, epilepsy, arrhythmia, myotonia, ataxia, multiple sclerosis, irritable bowel syndrome, urinary incontinence, visceral pain, depression, erythromelalgia, paroxysmal extreme pain disorder (PEPD).
    Type: Grant
    Filed: February 11, 2016
    Date of Patent: March 17, 2020
    Assignee: Daewoong Pharmaceutical Co., Ltd.
    Inventors: Ji Duck Kim, Hyung Geun Lee, Inwoo Kim, Sun Ah Jun, Myunggi Jung, Hyo Shin Kim
  • Publication number: 20200061241
    Abstract: The present invention relates to a composition for dermal injection which includes two or more types of cross-linked hyaluronic acid particles having different particle diameters and non-cross-linked hyaluronic acid. The composition for dermal injection according to the present invention satisfies viscosity, extrusion force, and viscoelasticity conditions for dermal injection, and an extrusion force deviation is low so that the user does not feel fatigue when the composition is injected into the dermal thereof. Also, the composition is excellent in viscoelasticity and tissue restoring ability, is maintained for a long period of time, allows rapid recovery because an initial swelling degree is low, and also is excellent in safety and stability in the body.
    Type: Application
    Filed: February 27, 2018
    Publication date: February 27, 2020
    Applicants: CG Bio Co., Ltd., DNCompany, Daewoong Pharmaceutical Co., Ltd.
    Inventors: Ji Sun LEE, Su Hyun JUNG, Hak Su JANG, Jung Eun CHOO, Hye Young JUNG
  • Publication number: 20200046762
    Abstract: The present invention relates to a suspension comprising smectite, and the suspension of the present invention comprises both a polymeric suspending agent and a low molecular suspending agent, and thus exhibits high dispersibility and sinking rate, ease of administration due to not high viscosity of a formulation, enhanced drug compliance while taking the formulation, and high preference. In addition, the suspension of the present invention enables uniform dispersion in preparation thereof, thus exhibiting ease of preparation and excellent efficiency, and accordingly, has an excellent effect on reducing a defect rate in the production of a suspension preparation.
    Type: Application
    Filed: April 12, 2018
    Publication date: February 13, 2020
    Applicants: Daewoong Pharmaceutical Co., Ltd., Liaoning Daewoong Pharmaceutical Co., Ltd.
    Inventors: Ye CHANG, Qing Ri LI, Sang Ho SEOL, Tie LI, Chao TONG
  • Publication number: 20200016191
    Abstract: The present invention relates to a composition for dermal injection which includes two or more types of cross-linked hyaluronic acid particles having different particle diameters and non-cross-linked hyaluronic acid. The composition for dermal injection according to the present invention satisfies viscosity, extrusion force, and viscoelasticity conditions for dermal injection, and an extrusion force deviation is low so that the user does not feel fatigue when the composition is injected into the dermal thereof. Also, the composition is excellent in viscoelasticity and tissue restoring ability, is maintained for a long period of time, allows rapid recovery because an initial swelling degree is low, and also is excellent in safety and stability in the body.
    Type: Application
    Filed: February 27, 2018
    Publication date: January 16, 2020
    Applicants: CG Bio Co., Ltd., DNCompany, Daewoong Pharmaceutical Co., Ltd.
    Inventors: Ji Sun LEE, Su Hyun JUNG, Hak Su JANG, Jung Eun CHOO, Hye Young JUNG
  • Publication number: 20190382390
    Abstract: The present invention relates to an improved method for producing a diphenylmethane derivative which is effective as a sodium-dependent glucose cotransporter (SGLT) inhibitor, the method being carried out by means of a convergent synthesis method in which each major group is separately synthesized and then coupled. As such, in comparison to a linear synthesis method disclosed in existing documents, the synthesis pathway is compact and yield can be increased, and risk factors inherent in the linear synthesis pathway can be reduced. Furthermore, the crystal form of the compound produced according to the method has superb physicochemical characteristics, and thus can be effectively utilized in fields such as pharmaceutical manufacturing.
    Type: Application
    Filed: August 30, 2019
    Publication date: December 19, 2019
    Applicants: DAEWOONG PHARMACEUTICAL CO., LTD., GREEN CROSS CORPORATION
    Inventors: Hee-kyoon YOON, Se-Hwan PARK, Ji-sung YOON, Soongyu CHOI, Hee Jeong SEO, Eun-Jung PARK, Younggyu KONG, Kwang-Seop SONG, Min Ju KIM, So Ok PARK
  • Publication number: 20190374457
    Abstract: The present invention relates to a composition for dermal injection which includes two or more types of cross-linked hyaluronic acid particles having different particle diameters and non-cross-linked hyaluronic acid. The composition for dermal injection according to the present invention satisfies viscosity, extrusion force, and viscoelasticity conditions for dermal injection, and an extrusion force deviation is low so that the user does not feel fatigue when the composition is injected into the dermal thereof. Also, the composition is excellent in viscoelasticity and tissue restoring ability, is maintained for a long period of time, allows rapid recovery because an initial swelling degree is low, and also is excellent in safety and stability in the body.
    Type: Application
    Filed: February 27, 2018
    Publication date: December 12, 2019
    Applicants: CG Bio Co., Ltd., DNCompany, Daewoong Pharmaceutical Co., Ltd.
    Inventors: Ji Sun LEE, Su Hyun JUNG, Hak Su JANG, Jung Eun CHOO, Hye Young JUNG
  • Patent number: 10487053
    Abstract: The present invention provides a novel acid addition salt of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine. The above-described acid addition salt can have not only excellent proton pump inhibitory activity, gastric damage inhibitory activity and defensive factor-enhancing effect, but also excellent eradication activity against H. pylori and thus can be effectively used for the prevention and treatment of gastrointestinal injury due to gastrointestinal track ulcer, gastritis, reflux esophagitis, or H. pylori.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: November 26, 2019
    Assignee: Daewoong Pharmaceutical Co., Ltd.
    Inventors: Aeri Kim, Kwan Hyung Cho
  • Patent number: 10399988
    Abstract: The present invention relates to 4-aminopyrazolo[3,4-d]pyrimidinylazabicyclo derivatives and pharmaceutical compositions containing the same, wherein the 4-aminopyrazolo[3,4-d]pyrimidinylazabicyclo derivatives and pharmaceutical compositions containing them not only have BTK inhibitory activity but also has remarkably high selectivity for the inhibitory activity of BTK vs. ITK, and thereby can be usefully used for the prevention or treatment of autoimmune diseases or cancers as BTK inhibitors.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: September 3, 2019
    Assignee: Daewoong Pharmaceutical Co., Ltd.
    Inventors: Youn-Jung Yoon, Jung-Eun Park, Yeon-Jung Park, Min-June Shim, Keuk-Chan Bang, Joon-Seok Park
  • Patent number: 10336695
    Abstract: The present invention provides a novel crystalline form I of hydrochloride, a crystalline form II of hydrochloride, a crystalline form of succinate, a crystalline form of tartrate, a crystalline form I of fumarate and a crystalline form II of fumarate of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine. The above-described novel crystalline forms have high solubility in water and excellent stability under moisture-proof conditions and high-humidity exposure conditions, and thus can be pharmaceutically used.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: July 2, 2019
    Assignee: Daewoong Pharmaceutical Co., Ltd.
    Inventors: Aeri Kim, Kwan Hyung Cho